CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.
CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.
复制标题
DOI：
10.1371/journal.pone.0026399
复制
发表时间：
2011
期刊：
影响因子：
3.7
通讯作者：
Chen W
中科院分区：
文献类型：
--
作者：
Feng Z;Guo W;Zhang C;Xu Q;Zhang P;Sun J;Zhu H;Wang Z;Li J;Wang L;Wang B;Ren G;Ji T;Tu W;Yang X;Qiu W;Mao L;Zhang Z;Chen W
细胞周期蛋白D_1(CCND_1)与化疗耐药和预后不良有关。在这项研究中，我们验证了CCND1表达决定局部晚期头颈部鳞状细胞癌(HNSCC)患者的疗效和临床结果的假设，这些患者在接受新辅助化疗后接受手术和放射治疗。2 2 4例鼻咽癌患者接受以顺铂为主的化疗加手术加放疗(新辅助组，n = 10 0)或手术加放疗(非新辅助组，n = 12 4)治疗。免疫组织化学方法检测CCND1的表达。以化疗反应、无瘤生存期(DFS)和总生存期(OS)为指标分析CCND1水平。新辅助化疗组与非新辅助化疗组在DFS和OS方面差异无统计学意义(p = 0.929和p = 0.760)。然而，在新辅助组中，肿瘤中ccnd1低表达的患者更有可能对化疗有反应(p<；0.001)，其OS和DFS明显好于那些肿瘤ccnd1高表达的患者(73%vs8%，p<；0.001；63%vs6%，p<；0.001)。重要的是，新辅助组中CCND1低表达的患者比非新辅助组获得了更多的生存益处(p = 0.016)，而接受新辅助化疗的CCND1高表达患者的OS显著低于手术和放疗组(p = 0.032)。多因素生存分析也显示CCND1mRNA的表达是一个独立的预测因素(p<；0.001)。本研究提示，部分(但不是全部)HNSCC患者可能受益于以顺铂为基础的新辅助化疗方案，CCND1的表达可作为选择接受少于两个周期新辅助化疗的患者的预测生物标志物。
Cyclin D1 (CCND1) has been associated with chemotherapy resistance and poor prognosis. In this study, we tested the hypothesis that CCND1 expression determines response and clinical outcomes in locally advanced head and neck squamous cell carcinoma (HNSCC) patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. 224 patients with HNSCC were treated with either cisplatin-based chemotherapy followed by surgery and radiotherapy (neoadjuvant group, n = 100) or surgery and radiotherapy (non-neoadjuvant group, n = 124). CCND1 expression was assessed by immunohistochemistry. CCND1 levels were analyzed with chemotherapy response, disease-free survival (DFS) and overall survival (OS). There was no significant difference between the neoadjuvant group and non-neoadjuvant group in DFS and OS (p = 0.929 and p = 0.760) when patients treated with the indiscriminate administration of cisplatin-based chemotherapy. However, in the neoadjuvant group, patients whose tumors showed a low CCND1 expression more likely respond to chemotherapy (p<0.001) and had a significantly better OS and DFS than those whose tumors showed a high CCND1 expression (73% vs 8%, p<0.001; 63% vs 6%, p<0.001). Importantly, patients with a low CCND1 expression in neoadjuvant group received more survival benefits than those in non-neoadjuvant group (p = 0.016), however patients with a high CCND1 expression and treated with neoadjuvant chemotherapy had a significantly poor OS compared to those treated with surgery and radiotherapy (p = 0.032). A multivariate survival analysis also showed CCND1 expression was an independent predictive factor (p<0.001). This study suggests that some but not all patients with HNSCC may benefit from neoadjuvant chemotherapy with cisplatin-based regimen and CCND1 expression may serve as a predictive biomarker in selecting patients undergo less than two cycles of neoadjuvant chemotherapy.
登录
查看更多内容
影响因子：
45.3
作者：
Kelsen, David P.;Winter, Katryn A.;Willett, Christopher G.
通讯作者：
Willett, Christopher G.
影响因子：
3.2
作者：
Allen, PJ;Kemeny, N;Fong, Y
通讯作者：
Fong, Y
影响因子：
2.6
作者：
Beauvillain, C;Mahe, M;Wesoluch, M
通讯作者：
Wesoluch, M
头颈癌中辅助化疗的随机对照试验的概述。
影响因子：
8.8
作者：
Munro, A J
通讯作者：
Munro, A J
影响因子：
11.5
作者：
Rudas, Margaretha;Lehnert, Martina;Filipits, Martin
通讯作者：
Filipits, Martin